| Project/Area Number |
22591505
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TASHIRO Hirotaka 広島大学, 大学院・医歯薬保健学研究院, 准教授 (90359894)
OHDAN Hideki 広島大学, 大学院・医歯薬保健学研究院, 教授 (10363061)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 胆管細胞癌 / Death receptor / NK細胞療法 / ムチンタンパク / ムチンコアタンパク |
|---|
| Research Abstract |
We investigated the new strategy of natural killer (NK) cell therapy for patients with cholangiocellular carcinoma (CCC) and mixed liver cancer that were highly malignant type of liver cancer. According to our clinical specimens of CCC, more than 90% of patients elevated DR-4 expression. On the other hand, we could detect that MUC5 was one of the independent prognostic factors in survival of CCC patients. We have also confirmed human NK cells killed HuCCT1 which was cell line of human CCC, in dose dependent manner. The facts would indicated the possibility of NK cell therapy with death receptor and Ab-dependent immune response for CCC patients.
|
